[HTML][HTML] Hepatitis B virus–specific T cells associate with viral control upon nucleos (t) ide-analogue therapy discontinuation
The Journal of clinical investigation, 2018•Am Soc Clin Investig
BACKGROUND. The clinical management of chronic hepatitis B virus (HBV) patients is
based exclusively on virological parameters that cannot independently determine in which
patients nucleos (t) ide-analogue (NUC) therapy can be safely discontinued. NUCs
efficiently suppress viral replication, but do not eliminate HBV. Thus, therapy discontinuation
can be associated with virological and biochemical relapse and, consequently, therapy in
the majority is life-long. METHODS. Since antiviral immunity is pivotal for HBV control, we …
based exclusively on virological parameters that cannot independently determine in which
patients nucleos (t) ide-analogue (NUC) therapy can be safely discontinued. NUCs
efficiently suppress viral replication, but do not eliminate HBV. Thus, therapy discontinuation
can be associated with virological and biochemical relapse and, consequently, therapy in
the majority is life-long. METHODS. Since antiviral immunity is pivotal for HBV control, we …
BACKGROUND. The clinical management of chronic hepatitis B virus (HBV) patients is based exclusively on virological parameters that cannot independently determine in which patients nucleos(t)ide-analogue (NUC) therapy can be safely discontinued. NUCs efficiently suppress viral replication, but do not eliminate HBV. Thus, therapy discontinuation can be associated with virological and biochemical relapse and, consequently, therapy in the majority is life-long.
METHODS. Since antiviral immunity is pivotal for HBV control, we investigated potential biomarkers for the safe discontinuation of NUCs within immune profiles of chronic HBV patients by utilizing traditional immunological assays (ELISPOT, flow cytometry) in conjunction with analyses of global non–antigen-specific immune populations (NanoString and CyTOF). Two distinct cohorts of 19 and 27 chronic HBV patients, respectively, were analyzed longitudinally prior to and after discontinuation of 2 different NUC therapy strategies.
RESULTS. Absence of hepatic flares following discontinuation of NUC treatment correlated with the presence, during NUC viral suppression, of HBV core and polymerase-specific T cells that were contained within the ex vivo PD-1+ population.
CONCLUSIONS. This study identifies the presence of functional HBV-specific T cells as a candidate immunological biomarker for safe therapy discontinuation in chronic HBV patients. Furthermore, the persistent and functional antiviral activity of PD-1+ HBV–specific T cells highlights the potential beneficial role of the expression of T cell exhaustion markers during human chronic viral infection.
FUNDING. This work was funded by a Singapore Translational Research Investigator Award (NMRC/STaR/013/2012), the Eradication of HBV TCR Program (NMRC/TCR/014-NUHS/2015), the Singapore Immunology Network, the Wellcome Trust (107389/Z/15/Z), and a Barts and The London Charity (723/1795) grant.
The Journal of Clinical Investigation